Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Available from: 6
A significant number of patients with multiple myeloma continue to relapse and become refractory to currently available therapies, representing one of the largest and most challenging unmet needs in the disease, Ester in t Groen, EMEA Therapeutic Area head, Haematology, at Johnson & Johnson, stated in a news release.1 Making teclistamab monotherapy available to patients as early as second line, where it has the potential to meaningfully improve long-term outcomes and change the course of the disease, could bring new hope to patients and their families. To view or add a comment, sign in 7,166 followers
Novo Nordisk has a savings program that may help with your out-of-pocket costs
Finalmente, evaluar el rendimiento tcnico de los ttulos y la estabilidad de los servidores aporta tranquilidad
The simple truth is that results are real but a little different for everyone
US$ 21.34
US$ 26.83
US$ 20.74
